finmarketnews.com
news-details
Healthcare & Biotech,Insiders

ALZN Showing Recent Insider Activity

Recent activity shows that Alzamend Neuro, ALZN the Insider Confidence level is trending Up due to Corporate Insiders of ALZN Bought $224.7K worth of shares in the last 3 months.  

Before you dig into this report it is important to remember that "Insider Buying" is the purchase of shares in a corporation by a director, officer, or executive within the company. Insider buying is not the same as insider trading, which refers to corporate insiders making illegal stock purchases based on non-public information.
 
"Insider Buying" is not a crime when the buying is based on public information. 
 
Additionally, since insiders have unique insights into their own companies, they often gobble up shares when they believe the stock is undervalued or dump stock when it’s time to sell.  That's why people pay attention to insider buying.

Here is a list of the latest insider activity for ALZN:
  • McGrath Lynne Fahey - Director, Bought $30,250 worth of shares on 1 week ago
  • AULT MILTON C III - >10% Owner, Bought $56,000 worth of shares on 2 days ago
  • Mark Gustafson - Director, Sold $24,200 worth of shares on 1 week ago
  • AULT MILTON C III - >10% Owner, Bought $110,000 worth of shares on 3 weeks ago
TipRanks.com reports that Alzamend Neuro currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $15.00 . The target pricing ranges from a high forecast of $15.00 down to a low forecast of $15.00. Alzamend Neuro (ALZN)’s last closing price was 1.04 which would put the average price target at 1342.31% upside.

In addition, TradingView issued a Sell rating for ALZN over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook

Alzamend Neuro, ALZN
Summary: Alzamed Neuro is an early clinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Their mission is to rapidly develop and market safe and effective treatments. Their current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
  • Last Price: 1.04
  • Price Change: >-0, -5.45%
  • Yearly Gain: -91.85%
  • Market Cap: 93.71M
  • P/E Ratio: -17.944
Remember, securities are volatile, so please do your own research on ALZN. If you are interest in stocks like ALZN or stocks in the Healthcare sector, please click here.

TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>

When an ALZN analyst reiterates coverage on stocks, we will let you know.  Please make sure you subscribe to our email newsletter to get timely alerts. Join thousands of other investors, you can always unsubscribe.

This information was sourced from various 3rd party public sources but to get the best insight into insider activity related to ALZN, you should consider joining TipRanks.com.

Disclaimer:
 Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data.
Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.    
==============================================================================